Thoracic Oncology Group of Australasia

Treatments and Research

Get the latest news, treatments, ASM highlights and topics in lung cancer and mesothelioma from The Thoracic Oncology Group of Australasia (TOGA).

Post Category Filter Radio Buttons
Two years ago, thanks to the generosity of our philanthropic donors, TOGA awarded the first ever Inspirational Research Grants. Read their final achievements.
Learn how tarlatamab targets DLL3, the evidence from the DeLLphi clinical trials, and the current Australian access pathway for relapsed small cell lung cancer.
Learn how antibody-drug conjugates (ADCs) work in lung cancer, the major clinical trials, emerging biomarkers and how these targeted therapies are changing treatment.
Bispecific antibodies bind two different targets at once, reshaping lung cancer treatment through dual checkpoint blockade and targeted precision.
Occasionally, there will be one presentation that stands out for a different reason. See why Dr Prem Ram's talk changed the game.
Learn what a KRAS G12C mutation means, how targeted therapies work, and how Australian clinical trials are testing new lung cancer treatments.
New evidence is changing the way surgeons approach early-stage lung cancer, with lung-sparing surgery becoming an option for carefully selected patients.
Clinicians, nurses, consumers and health service leaders came together at TOGA’s Lung Cancer Optimal Care Pathway workshop to examine why Australia continues to struggle to
Learn why EGFR-positive lung cancer disproportionately affects Asian populations and non-smokers. Discover modern targeted therapies and symptoms to watch for.
Discover how 2025 transformed lung cancer care in Australia. Explore the impact of national screening, modern diagnostics, and new PBS treatment approvals.
The final Scientific Meeting of 2025 was held in November. Five concepts were presented, spanning both Recurrent and Metastatic NSCLC populations and four Mesothelioma concepts.
Liquid biopsy is revolutionising lung cancer care by using a blood test to examine the tumour without the need for a lung biopsy.
Why doesn’t immunotherapy work for all lung cancer patients? This article breaks down T-cell resistance mechanisms and what clinical trials are doing to overcome them.
Precision medicine has revolutionised lung cancer treatment by matching therapies to a patient’s genetic profile. Learn more.....
On May 2, 2023, the Australian Government announced a significant investment of $263.8 million over four years to establish the national Lung Cancer Screening Program
Explore the research behind lung cancer vaccines, including mRNA and personalised approaches. Understand the potential for prevention and treatment, plus the latest clinical trial updates.
The Thoracic Oncology Group of Australasia (TOGA) is thrilled to announce the recipients of the 2025 Inspirational Research Grants.
The Inspirational Research Grant has been created from philanthropic donations to increase research into prevention, treatment, or improved lives of those living with thoracic cancers.
The Inspirational Research Grant has been created from philanthropic donations to increase research into prevention, treatment, or improved lives of those living with thoracic cancers.
The Inspirational Research Grant has been created from philanthropic donations to increase research into prevention, treatment, or improved lives of those living with thoracic cancers.
ALK Positive Australia Inc. and the Thoracic Oncology Group of Australia (TOGA) are honoured to announce a new grant partnership dedicated to advancing ALK+ NSCLC
We’ve all seen the exciting ‘practice-changing’ results presented at conferences like ESMO 2023. But how do these new cancer treatments become available for everyday use
We’ve all seen the exciting ‘practice-changing’ results presented at conferences like ESMO 2023. But how do these new cancer treatments become available for everyday use